💸 The Tape

For decades, the idea of registering a cannabis dispensary with the Drug Enforcement Administration would have sounded like the setup to a very bad joke — or a very effective sting operation. As of Wednesday morning, it's just paperwork.

The DEA will open its new Medical Marijuana Dispensary Registration Portal on April 29 at 9:00 a.m. Eastern, giving state-licensed medical cannabis operators a formal pathway to register with the federal government for the first time in history. The portal, hosted through the DEA's Diversion Control Division, represents one of the most tangible, ground-level consequences of last week's landmark rescheduling order that moved state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act.

It's real. It's online. And it accepts PayPal.

How It Works

The registration process is structured across seven sections: personal and business information, activity type, state licenses, liability questions, compliance details, payment, and submission. Applicants will need to provide business and contact information, ownership details, tax identification or Social Security numbers, and documentation of their state medical marijuana licenses.

The application asks whether the business is requesting to handle marijuana, marijuana extract, or naturally derived delta-9-THC — and whether those substances are part of an FDA-approved product or covered under a state medical marijuana license. Notably, applicants must also disclose whether they handle or dispense medical marijuana, recreational marijuana, or both — a distinction that matters significantly under the current rescheduling framework, where only medical cannabis has been reclassified.

The compliance section digs into operational specifics: supplier information, standard operating procedures, and security measures including whether the facility has a vault, safe, secure storage room, access controls, alarm system, or onsite security personnel. It's the kind of regulatory infrastructure that signals the federal government is treating medical cannabis operators like what they are — legitimate pharmaceutical businesses — rather than criminal enterprises to be monitored from a distance.

Once submitted, applicants receive a confirmation notice and email. The annual application fee is $794, nonrefundable, with PayPal as the only current payment method — though the DEA says additional payment options are expected in the coming weeks.

Why This Matters More Than It Looks

On the surface, a government registration portal is about as exciting as a DMV appointment. But in the context of cannabis, this is quietly revolutionary.

For the entire history of state-legal medical marijuana in the United States — spanning 40 states and two decades of legislative expansion — operators have existed in a regulatory no-man's-land. They held state licenses, paid state taxes, served patients, and built businesses, all while the federal government classified their core product alongside heroin and LSD. There was no federal registration pathway because, in the eyes of the DEA, there was no legitimate medical marijuana business to register.

That changed last week when Acting Attorney General Todd Blanche issued the final order rescheduling state-licensed medical cannabis to Schedule III. The order didn't just reclassify the substance — it established an expedited DEA registration pathway that integrates existing state licensing frameworks into the federal system. Operators who submit applications within 60 days of the order's publication — by June 22, 2026 — may continue operating under their state licenses while the DEA processes their registrations. The agency has committed to processing those early applications within six months.

The registration portal is the mechanism that makes all of that real. It's the front door to federal legitimacy.

The Compliance Signal

The portal's compliance requirements tell you a lot about how the federal government intends to treat Schedule III cannabis operations. The security questions — vaults, safes, access controls, alarm systems, onsite personnel — mirror the compliance frameworks applied to other Schedule III substances like ketamine and anabolic steroids. That's not a casual comparison. It means medical cannabis operators are being folded into an existing, well-understood regulatory architecture rather than having something entirely new built around them.

For operators who have spent years building seed-to-sale tracking systems, implementing state-mandated security protocols, and maintaining detailed compliance records, the federal requirements are unlikely to represent a dramatic operational lift. In many cases, state-level compliance standards — particularly in tightly regulated markets like Florida, Pennsylvania, and Ohio — already meet or exceed what the DEA is asking for.

That's the quiet advantage of the rescheduling order's design: by anchoring federal registration to existing state licensing infrastructure, it avoids creating a duplicative regulatory layer that could have paralyzed the industry. Operators don't need to rebuild from scratch. They need to file the paperwork.

What It Means for the Big Operators

For the largest multi-state operators — companies like Trulieve, Curaleaf, and Green Thumb Industries — the registration portal represents the administrative starting line for capturing the benefits of rescheduling. Federal registration is the prerequisite for 280E tax relief, which eliminates the punitive tax provision that has cost the industry an estimated $15 billion since 2018.

These companies operate medical programs across dozens of states. Each dispensary location, each cultivation facility, each processing operation that qualifies under a state medical license will need to register through the DEA portal. The scale of that administrative undertaking is significant — but so is the financial payoff on the other side.

Companies that move quickly to register within the 60-day window gain the dual benefit of continued operations under existing state licenses and positioning at the front of the DEA's processing queue. In an industry where timing has always been the difference between advantage and irrelevance, early movers will be rewarded.

The Bigger Picture

The DEA's registration portal is not legalization. It's not the end of the federal-state tension that has defined cannabis policy for a generation. Recreational marijuana remains Schedule I. The broader hearing on full rescheduling doesn't begin until June 29. And the IRS has yet to issue formal guidance on how 280E relief will be implemented in practice.

But sometimes the most significant shifts aren't the dramatic ones. They're the bureaucratic ones — the moments when a government agency builds a website, sets a fee, and says: come register your business. We're ready for you.

After fifty years of prohibition, the DEA just opened the door. The industry should walk through it.

📈 Dog Walkers

$TSNDF ( ▲ 19.23% ) Releases Preliminary Results

The North American cannabis operator released preliminary Q1 2026 results showing a return to year-over-year revenue growth from continuing operations, with net revenue of $65.5 million — up from $64.3 million in Q1 2025 and essentially flat against Q4 2025's $66.1 million. Gross profit margins came in at 52.8%, slightly ahead of the prior quarter's 52.1% and just below the year-ago period's 53.9%. G&A expenses held flat quarter-over-quarter, and the company generated positive cash flow from operations for the 15th consecutive quarter.

These aren't explosive numbers, but they reflect exactly the kind of disciplined, steady execution that positions a company to capitalize when the landscape shifts — and it just did.

Executive Chairman Jason Wild didn't bury the headline, citing last week's federal rescheduling of medical cannabis to Schedule III as a catalyst that has "the team more excited than ever about the future." For TerrAscend, which operates significant medical cannabis programs across its core markets, the elimination of the 280E tax burden on qualifying medical operations could meaningfully improve after-tax profitability without the company needing to change a single operational variable.

Fifteen straight quarters of positive operating cash flow is a track record that matters when the industry's biggest structural headwind suddenly starts lifting. Combined with what Wild described as a strong balance sheet and disciplined approach to capital allocation and M&A, TerrAscend is positioning itself as the kind of operator that can move decisively when opportunities emerge — rather than scrambling to stabilize while the market evolves around it.

Full Q1 details and forward outlook will come on the company's upcoming earnings call.

$MEDIF ( ▲ 5.25% ) Is Back?

The Canadian pharmaceutical cannabis company wasted no time responding to last week's DEA final order rescheduling state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III. And unlike operators positioning themselves for future opportunity, MediPharm's pitch is built on a track record that already exists.

The company has supplied product for over 10 active clinical trials — including a U.S. National Institutes of Health-funded study — and has completed multiple API and clinical trial material shipments to the United States. Those shipments were made under Schedule I conditions, meaning MediPharm navigated the most restrictive federal controls applied to any substance in American law. With Schedule III now in effect, that pathway becomes significantly less burdensome.

"MediPharm Labs is not approaching the U.S. market for the first time," said Interim CEO and CFO Greg Hunter. "Since 2023, we have shipped pharmaceutical-grade cannabis product into the United States multiple times under Schedule I conditions." He pointed to the company's established presence in some of the world's toughest regulatory markets — Germany, the United Kingdom, Australia, France, and Brazil — as proof of capability.

The strategic positioning is precise. MediPharm holds both a U.S. FDA site registration and a Health Canada Drug Establishment License (DEL), giving it the compliance infrastructure to serve as a compliant API and clinical trial supply partner for U.S. researchers and pharmaceutical companies. As rescheduling removes barriers that have historically limited full clinical trials — despite thousands of peer-reviewed cannabis studies being published annually — demand for standardized, pharmaceutical-grade cannabis supply is expected to accelerate.

There's also a capital markets angle. With Schedule I's "trafficking" classification removed for medical cannabis, institutional investors previously restricted by compliance policies may now be able to consider research-oriented cannabis companies. That could unlock a new tier of investment interest from pharmaceutical firms and funds that avoided the sector entirely under the old classification.

MediPharm isn't a dispensary operator or a consumer brand. It's a pharmaceutical manufacturing platform built for exactly the regulatory environment that just arrived. While the rest of the industry celebrates rescheduling as a milestone, MediPharm is treating it as a starting gun for a race it's already been running.

🗞️ The News

📺 YouTube

Options Trading Cannabis & Psychedelics + Farm Bill Debate | TTB Presented by Flowhub

What we will cover:

✅ In our latest Trade To Black podcast presented by Flowhub, hosts Shadd Dales and Anthony Varrell break down two conversations that are front and center right now: how to approach options trading in cannabis and psychedelic stocks, and the growing debate around the Farm Bill and hemp regulation.

In segment one, Matthew “WHIZ” Buckley — former Top Gun fighter pilot and founder of Top Gun Options — joins the show to talk specifically about options trading in catalyst-driven markets.

With psychedelics moving after President Trump’s executive order on research, and cannabis stocks still reacting to rescheduling, volatility is back across both sectors. WHIZ walks through how traders should be thinking in these environments, what tends to get overlooked, and how to better prepare when markets start moving quickly around policy-driven headlines.

In segment two, Michael Bronstein, President of the American Trade Association for Cannabis & Hemp, joins for the Insider’s Edge.

We get into what’s happening right now with the Farm Bill conversation, the ongoing debate around hemp-derived THC products, and why this is becoming one of the most important policy battles in the industry. We also touch on Pennsylvania’s adult-use push and where things stand in Virginia after lawmakers rejected Governor Abigail Spanberger’s proposed changes.